SS
CNTX icon

SBI Securities’s Context Therapeutics CNTX Stock Holding History

SBI Securities’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43 Hold
78
– – ﹤0.01% 3703
2026
Q1 		$204 Sell
78
-36
-32% -$84 ﹤0.01% 3209
2025
Q4 		$168 Sell
114
-3
-3% -$4 ﹤0.01% 3264
2025
Q3 		$113 Buy
117
+4
+4% +$3 ﹤0.01% 3481
2025
Q2 		$74 Hold
113
– – ﹤0.01% 3622
2025
Q1 		$69 Hold
113
– – ﹤0.01% 3559
2024
Q4 		$119 Buy
+113
New +$196 ﹤0.01% 3407

Other funds holding CNTX

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SBI Securities's CNTX Position: Q2 2026 in Review

SBI Securities held its Context Therapeutics (CNTX) position steady in Q2 2026 at 78 shares worth $43. The position accounts for ﹤0.01% of the portfolio, ranked #3703.

SBI Securities first reported a position in CNTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $204 in Q1 2026. 43 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • SBI Securities held 78 shares of Context Therapeutics worth $43 as of Q2 2026.
  • SBI Securities left its Context Therapeutics share count unchanged in Q2 2026.
  • Context Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3703 holding.
  • SBI Securities first reported a position in Context Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Context Therapeutics position peaked at $204 in Q1 2026.
  • 43 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.